Peloo Odi Tablet 20 mg (Memantine Hydrochloride)

Adult dose

This medication is administered orally once daily and must be taken at the same time each day. If necessary, it may be administered twice daily. For the first 3 weeks, the dose is increased by 5 mg per week. - First week (days 1-7): 5 mg daily - Second week (days 8-14): 10 mg daily - Third week (days 15-21): 15 mg daily - From the fourth week: 20 mg daily Recommended.

This medication contains the artificial sweetener aspartame, which is broken down in the body into phenylalanine. Therefore, patients with phenylketonuria, a hereditary condition that requires restriction of phenylalanine intake, should not take this medication. The daily intake of aspartame should be limited to below the WHO recommended amount of 40 mg/kg, and for a 60 kg adult, care should be taken not to exceed a maximum of 2.4 g per day. Persons who are hypersensitive to the components of this medication, or have severe liver or kidney dysfunction should avoid taking it. In particular, it should not be administered to those with severely impaired kidney function (creatinine clearance less than 5 mL/min). Additionally, since this medication contains lactose, patients with genetic problems such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption should not take it. Patients with epilepsy or a history of seizures, or those with a predisposition to seizures should use this medication cautiously. Concurrent use with other medications that act on the NMDA receptor may increase central nervous system side effects, so co-administration should be avoided. Care should also be taken in situations that may increase urinary pH, such as changes in diet or certain urinary tract infections, and patients with recent myocardial infarction, congestive heart failure, or uncontrolled hypertension should use this medication carefully. Taking this medication may cause side effects such as dizziness, headache, constipation, drowsiness, and hypertension; central nervous system symptoms such as hallucinations or psychotic reactions have also been reported in some patients. This medication may interact with other drugs; special caution is required when taken with NMDA antagonists, antipsychotics, skeletal muscle relaxants, anticoagulants, and certain gastrointestinal medications due to potential drug concentration changes or increased risk of side effects, and consultation with a doctor or pharmacist is recommended. Pregnant women should use this medication only when deemed necessary due to the risk to the fetus; breastfeeding women are advised to stop breastfeeding as this medication may pass into breast milk. Use in children or adolescents under 18 years is not recommended as the safety and effectiveness of this medication have not been established. In the event of overdose, symptoms such as drowsiness, confusion, hallucinations, seizures, and vomiting may occur; in such cases, prompt medical attention should be sought. This medication may diminish the patient's responsiveness, so caution should be taken when driving or operating machinery. Finally, this medication should be kept out of the reach of children, and transferring it to another container should be avoided as it may pose a risk of accidents and degrade quality.

Serious side effects

Headache (severe headache, thunderclap headache, etc.), seizures, confusion, hallucinations, psychotic reactions, heart failure, thrombosis/thromboembolism, dyspnea, liver dysfunction (increased liver function test levels, hepatitis), severe edema, altered consciousness, paralysis, diplopia, coma, severe allergic reactions (including drug hypersensitivity reactions).

Mild side effects

• Dizziness
• headache
• constipation
• drowsiness
• hypertension
• fungal infection
• drug hypersensitivity reaction
• confusion
• hallucinations
• psychotic reactions

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is also recommended to keep it in a cool temperature below 30 degrees Celsius.

Appearance

Flat round orally disintegrating tablets with bright pink speckled pattern and edges.

Package unit

28 tablets/P-T-P [14 tablets/PTP x 2], 30 tablets/P-T-P [15 tablets/PTP x 2]